Roth Mkm Increases CervoMed (NASDAQ:CRVO) Price Target to $15.00

CervoMed (NASDAQ:CRVO) had its price objective raised by analysts at Roth Mkm from $7.00 to $15.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Roth Mkm’s price objective indicates a potential upside of 143.11% from the company’s current price.

CRVO has been the topic of several other research reports. Roth Capital upgraded shares of CervoMed to a “strong-buy” rating in a research report on Thursday, December 5th. Brookline Capital Management cut CervoMed from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Canaccord Genuity Group decreased their target price on CervoMed from $65.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Chardan Capital restated a “neutral” rating on shares of CervoMed in a research note on Wednesday, December 11th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of CervoMed in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $33.14.

CervoMed Trading Up 161.4 %

NASDAQ:CRVO opened at $6.17 on Tuesday. The firm’s fifty day simple moving average is $2.30 and its 200 day simple moving average is $8.20. CervoMed has a twelve month low of $1.80 and a twelve month high of $26.38.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC bought a new stake in CervoMed in the third quarter worth $56,000. Barclays PLC raised its position in shares of CervoMed by 323.6% in the 3rd quarter. Barclays PLC now owns 7,748 shares of the company’s stock worth $113,000 after purchasing an additional 5,919 shares during the last quarter. Virtu Financial LLC bought a new position in CervoMed in the 4th quarter worth about $26,000. DRW Securities LLC purchased a new stake in CervoMed during the 4th quarter valued at about $30,000. Finally, Mariner LLC purchased a new stake in CervoMed during the 4th quarter valued at about $30,000. Institutional investors own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.